Article

CMS expands coverage for verteporfin therapy

New York-The Centers for Medicare and Medicaid Services (CMS)-formerlythe Health Care Financing Administration-will begin reimbursing patientswho use verteporfin for injection (Visudyne) with occult choroidal neovascularization(CNV) lesions secondary to age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.